2. >>Archive

People In The News – Tracking The Latest Industry Personnel Moves

 
• By Gregory Twachtman

ImmunoCellular, WellPoint and EpiCept all are looking for new CEOs; former CMS Acting Administrator Kerry Weems joins Targeted Medical Pharma board; update on former FDA commissioner candidate Robert Califf; more personnel announcements in this month’s column.

Following the resignation of Manish Singh from his president and CEO position, ImmunoCellular Therapeutics Inc. announces that Chairman and Chief Scientific Officer John Yu will take over on an interim basis during the search for a permanent replacement … WellPoint Inc. is searching for a candidate to succeed Angela Braly as president, CEO and chairman. The company has named John Cannon, executive VP, general counsel, corporate secretary and Chief Public Officer as interim president and CEO … EpiCept Corp. introduces Robert Cook as interim president and CEO following the resignation of Jack Talley. Cook has been CFO since joining the company in April 2004 … Mark Meek takes over as president of the Biopharma Business Unit at the consultancy Decision Resources Group. He is a former CEO of Datamonitor … Akorn names Dinesh Dua CEO and managing director of the company’s India-based subsidiary Akorn India Pvt. Ltd. He joins the company from Nectar Lifesciences Ltd., where he was CEO … Randy Woods takes over as CEO of Sophiris Bio Inc., bringing more than 40 years of industry experience to his new role. He previously held the same title at Sequel Pharmaceuticals, NovaCardia Inc., and Corvas International … Nile Therapeutics promotes Darlene Horton to president and CEO. She joined the company in June 2012 as chief medical officer. Horton takes over for Joshua Kazam, who has held the title on a part-time basis since June 2009. Kazam remains on the company’s board of directors … AstraZeneca taps Pascal Soriot, former head of Roche’s pharmaceutical division and CEO of Genentech Inc., to serve as CEO Also see "AZ Taps Outsider Soriot As CEO, While Roche Anoints 25-Year Veteran O'Day To Head Pharma Division" - Pink Sheet, 28 August, 2012..

Dyax Corp. appoints Ivana Magovcevic-Liebisch to the newly created position of executive VP and chief operating officer. She has been with the company since April 2001, most recently as executive...

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 
• By Neena Brizmohun

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Nielsen Hobbs

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Nielsen Hobbs

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 
• By Francesca Bruce

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

US FDA Meeting Drought Ends … With A Vengeance

 
• By Michael McCaughan

The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

Could EU Collective Procurement Counter US Most Favored Nation Policy?

 
• By Francesca Bruce

Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.